BACKGROUND: Respiratory RNA viruses are associated with bronchiolitis obliterans syndrome (BOS) in lung transplant recipients (LTRS); however, the immune mechanisms that regulate airway obliteration remain incompletely understood. METHODS: Using the mouse heterotopic tracheal transplant model of obliterative airway disease (OAD), we studied the role of double-stranded (ds)RNA using polyinosinic:polycytidylic acid (poly[I:C]), a synthetic analog of viral dsRNA, in abrogating airway allograft tolerance established with donor-specific transfusion (DST) and anti-CD154 monoclonal antibody therapy. RESULTS: Wild-type (WT) B6 recipients of accepted BALB/c airway grafts demonstrated significantly reduced intragraft CD8+ T cells, with markedly impaired allospecific interferon (INF)-γ and tumor necrosis factor-α secretion, uncoupled from an activated phenotype, and evidence of proliferation. Administration of poly(I:C) to DST/anti-CD154-treated recipients restored OAD pathology and CD8+ alloeffector responses to levels observed in untreated mice. However, B6 type I IFN receptor-deficient (IFN-αβR(-/-)) recipients were resistant to the abrogation of tolerance mediated by poly(I:C) and did not develop CD8+ alloeffector responses or OAD. Further, adoptive transfers of WT CD8+ T cells or CD11c+ dendritic cells alone into B6 IFNαβR(-/-) recipients treated with poly(I:C) and DST/anti-CD154 were incapable of abrogating airway graft tolerance. CONCLUSIONS: Together, these data indicate abrogation of DST/anti-CD154-induced airway allograft tolerance via dsRNA requires type-I IFN responsiveness for mouse airway obliteration.
BACKGROUND:Respiratory RNA viruses are associated with bronchiolitis obliterans syndrome (BOS) in lung transplant recipients (LTRS); however, the immune mechanisms that regulate airway obliteration remain incompletely understood. METHODS: Using the mouse heterotopic tracheal transplant model of obliterative airway disease (OAD), we studied the role of double-stranded (ds)RNA using polyinosinic:polycytidylic acid (poly[I:C]), a synthetic analog of viral dsRNA, in abrogating airway allograft tolerance established with donor-specific transfusion (DST) and anti-CD154 monoclonal antibody therapy. RESULTS: Wild-type (WT) B6 recipients of accepted BALB/c airway grafts demonstrated significantly reduced intragraft CD8+ T cells, with markedly impaired allospecific interferon (INF)-γ and tumor necrosis factor-α secretion, uncoupled from an activated phenotype, and evidence of proliferation. Administration of poly(I:C) to DST/anti-CD154-treated recipients restored OAD pathology and CD8+ alloeffector responses to levels observed in untreated mice. However, B6 type IIFN receptor-deficient (IFN-αβR(-/-)) recipients were resistant to the abrogation of tolerance mediated by poly(I:C) and did not develop CD8+ alloeffector responses or OAD. Further, adoptive transfers of WT CD8+ T cells or CD11c+ dendritic cells alone into B6 IFNαβR(-/-) recipients treated with poly(I:C) and DST/anti-CD154 were incapable of abrogating airway graft tolerance. CONCLUSIONS: Together, these data indicate abrogation of DST/anti-CD154-induced airway allograft tolerance via dsRNA requires type-IIFN responsiveness for mouse airway obliteration.
Authors: Z Guo; L Meng; O Kim; J Wang; J Hart; G He; M L Alegre; J R Thistlethwaite; T C Pearson; C P Larsen; K A Newell Journal: Transplantation Date: 2001-05-15 Impact factor: 4.939
Authors: Yuan Zhai; Lingzhong Meng; Ronald W Busuttil; Mohamed H Sayegh; Jerzy W Kupiec-Weglinski Journal: J Immunol Date: 2003-03-15 Impact factor: 5.422
Authors: Yuan Zhai; Xiu-Da Shen; Feng Gao; Ana J Coito; Barbara A Wasowska; Alan Salama; Isabela Schmitt; Ronald W Busuttil; Mohamed H Sayegh; Jerzy W Kupiec-Weglinski Journal: J Immunol Date: 2002-08-01 Impact factor: 5.422
Authors: Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2011-10 Impact factor: 10.247
Authors: N D Jones; S E Turvey; A Van Maurik; M Hara; C I Kingsley; C H Smith; A L Mellor; P J Morris; K J Wood Journal: J Immunol Date: 2001-02-15 Impact factor: 5.422
Authors: John A Belperio; Michael P Keane; Marie D Burdick; Joseph P Lynch; Ying Ying Xue; Kewang Li; David J Ross; Robert M Strieter Journal: J Immunol Date: 2002-07-15 Impact factor: 5.422
Authors: Daniel T Dugger; Monica Fung; Lorna Zlock; Saharai Caldera; Louis Sharp; Steven R Hays; Jonathan P Singer; Lorriana E Leard; Jefferey A Golden; Rupal J Shah; Jasleen Kukreja; Erin Gordon; Walter Finkbeiner; Mary Ellen Kleinhenz; Chaz Langelier; John R Greenland Journal: Cell Rep Med Date: 2020-07-21